Cover Image
市場調查報告書

Pharis Biotec GmbH:產品平台分析

Pharis Biotec GmbH - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 256028
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
Pharis Biotec GmbH:產品平台分析 Pharis Biotec GmbH - Product Pipeline Review - 2014
出版日期: 2014年09月22日 內容資訊: 英文 29 Pages
簡介

Pharis Biotec GmbH 是轉譯、開發胜肽性醫藥品的生物製藥公司,主要致力於荷爾蒙·代謝疾病的心血管-腎臟系,神經及皮膚症候群治療藥的開發。

本報告提供Pharis Biotec GmbH的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,以及後期階段及中止的計劃等相關資訊。

Pharis Biotec GmbH的基本資料

  • Pharis Biotec GmbH概要
  • 主要資訊
  • 企業資料

Pharis Biotec GmbH:R&D概要

  • 主要的治療範圍

Pharis Biotec GmbH:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Pharis Biotec GmbH:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Pharis Biotec GmbH:藥物簡介

  • VIR-576
  • hPTH-1-37
  • ALB-408
  • CCL-14
  • LEKTI-6
  • Peptide for Herpes Simplex Infections
  • Peptide for Metabolic Diseases
  • VIR-353

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06345CDB

Summary

Global Markets Direct's, 'Pharis Biotec GmbH - Product Pipeline Review - 2014', provides an overview of the Pharis Biotec GmbH's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pharis Biotec GmbH's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Pharis Biotec GmbH including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Pharis Biotec GmbH's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Pharis Biotec GmbH's pipeline products

Reasons to buy

  • Evaluate Pharis Biotec GmbH's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Pharis Biotec GmbH in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Pharis Biotec GmbH's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Pharis Biotec GmbH and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pharis Biotec GmbH
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Pharis Biotec GmbH and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Pharis Biotec GmbH Snapshot
    • Pharis Biotec GmbH Overview
    • Key Information
    • Key Facts
  • Pharis Biotec GmbH - Research and Development Overview
    • Key Therapeutic Areas
  • Pharis Biotec GmbH - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Pharis Biotec GmbH - Pipeline Products Glance
    • Pharis Biotec GmbH - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Pharis Biotec GmbH - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Pharis Biotec GmbH - Drug Profiles
    • VIR-576
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hPTH-1-37
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALB-408
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CCL-14
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LEKTI-6
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide for Herpes Simplex Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide for Metabolic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VIR-353
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pharis Biotec GmbH - Pipeline Analysis
    • Pharis Biotec GmbH - Pipeline Products by Target
    • Pharis Biotec GmbH - Pipeline Products by Route of Administration
    • Pharis Biotec GmbH - Pipeline Products by Molecule Type
    • Pharis Biotec GmbH - Pipeline Products by Mechanism of Action
  • Pharis Biotec GmbH - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Pharis Biotec GmbH, Key Information
  • Pharis Biotec GmbH, Key Facts
  • Pharis Biotec GmbH - Pipeline by Indication, 2014
  • Pharis Biotec GmbH - Pipeline by Stage of Development, 2014
  • Pharis Biotec GmbH - Monotherapy Products in Pipeline, 2014
  • Pharis Biotec GmbH - Out-Licensed Products in Pipeline, 2014
  • Pharis Biotec GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2014
  • Pharis Biotec GmbH - Phase I, 2014
  • Pharis Biotec GmbH - Preclinical, 2014
  • Pharis Biotec GmbH - Discovery, 2014
  • Pharis Biotec GmbH - Pipeline by Target, 2014
  • Pharis Biotec GmbH - Pipeline by Route of Administration, 2014
  • Pharis Biotec GmbH - Pipeline by Molecule Type, 2014
  • Pharis Biotec GmbH - Pipeline Products by Mechanism of Action, 2014
  • Pharis Biotec GmbH, Subsidiaries

List of Figures

  • Pharis Biotec GmbH - Pipeline by Top 10 Indication, 2014
  • Pharis Biotec GmbH - Pipeline by Stage of Development, 2014
  • Pharis Biotec GmbH - Monotherapy Products in Pipeline, 2014
  • Pharis Biotec GmbH - Pipeline by Top 10 Target, 2014
  • Pharis Biotec GmbH - Pipeline by Top 10 Route of Administration, 2014
  • Pharis Biotec GmbH - Pipeline by Top 10 Molecule Type, 2014
  • Pharis Biotec GmbH - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top